US Biotech Earnings Show Split: Caris, TG Raise Targets While Early-Stage Firms Bleed Cash

The second-quarter earnings season of 2026 has laid bare a growing divide in the US healthcare and biotechnology sector. Commercial execution is increasingly dictating capital allocation, with companies holding approved portfolios posting robust revenue beats, while early-stage clinical developers are grappling with intensified cash-burn scrutiny.

Caris Life Sciences (CAI.US)

Caris Life Sciences (CAI.US) shares surged following its earnings release as the precision oncology firm reported a 45% jump in second-quarter total revenue to USD 263.7 million. According to people familiar with the financials, the beat was driven by a 55% expansion in molecular profiling services. The company subsequently raised its full-year 2026 revenue guidance to a range of USD 1.03 billion to USD 1.04 billion.

TG Therapeutics (TGTX.US)

Buoyed by the rapid commercial uptake of its multiple sclerosis treatment, TG Therapeutics (TGTX.US) posted Q2 total revenue of approximately USD 240 million. Net product revenue for BRIUMVI in the US reached USD 227.7 million, up 64% from the prior year. CEO Michael S. Weiss indicated the company is on track to achieve an annualized USD 1 billion run rate by the end of 2026, prompting a global revenue target hike.

Iovance Biotherapeutics (IOVA.US)

Cell therapy maker Iovance Biotherapeutics (IOVA.US) has been outperforming the broader market, reporting record Q2 revenue of USD 99.3 million, a 39% sequential increase. Its flagship TIL therapy Amtagvi generated roughly USD 91 million in the US alone. The company ended the quarter with USD 304 million in cash equivalents, which is expected to fund operations into the second half of 2028.

Exelixis (EXEL.US)

Exelixis (EXEL.US) saw its second-quarter total revenue climb to USD 628.7 million, anchored by USD 573 million in US net product revenue from its cabozantinib franchise. However, the company lowered its 2026 full-year revenue outlook to between USD 2.5 billion and USD 2.55 billion. To offset concerns over a flattening growth trajectory in its neuroendocrine tumor segment, management executed USD 311.6 million in share repurchases during the quarter.

Beam Therapeutics (BEAM.US)

Shares of gene-editing firm Beam Therapeutics (BEAM.US) have faced recent pressure after the company reported a widened net loss of USD 122.7 million for the second quarter, significantly missing Wall Street estimates. While the company achieved a critical milestone by dosing the first patient in its global BEAM-302 trial, analysts noted that lingering safety concerns surrounding off-target toxicities could limit near-term upside.

Upstream Bio (UPB.US)

Recent data from Upstream Bio (UPB.US) showed that 79% of participants receiving vereikitug in the Phase 2 VIBRANT trial achieved clinically meaningful improvements. Despite the clinical progress, regulatory filings show that BlackRock recently reduced its position by over 550,000 shares, reflecting broader institutional caution toward the liquidity of early-stage biotechs.

Beyond Meat (BYND.US)

As it attempts to pivot from a pure plant-based meat player to a broader health and nutrition brand, Beyond Meat (BYND.US) reported an 8.2% year-over-year drop in Q2 net revenue to USD 68.8 million. According to people familiar with the strategy, management is accelerating investments in European and Middle Eastern food service channels to offset a persistent 14.4% retail sales decline in the US market.

Propanc Biopharma (PPCB.US)

Propanc Biopharma (PPCB.US) recently released preclinical data showing its lead candidate PRP achieved over 90% tumor growth inhibition in pancreatic ductal adenocarcinoma models. Calling the stock undervalued, CEO James Nathanielsz authorized the completion of the first USD 500,000 tranche of a USD 5 million share buyback program as the firm advances its Phase 1b study in Australia.

Rain Therapeutics (RAIN.US)

Clinical-stage developer Rain Therapeutics (RAIN.US) continues to navigate the precision oncology space. While specific pipeline updates have been sparse this quarter, institutional investors tracking the sector are closely monitoring the firm's cash runway and enrollment rates for its targeted inhibitor programs.

Smartbird (BIRD.US)

Having officially rebranded from footwear maker Allbirds, Smartbird (BIRD.US) is pivoting into an AI infrastructure provider. The company reported Q2 revenue of USD 22.3 million alongside a net loss of USD 20.7 million. Following its recent board appointments of executives with healthcare backgrounds, the firm is targeting AI compute services tailored for data-heavy biomedical research.

This article does not constitute investment advice.